Alzheimer's Disease Diagnosis and Management in the Age of Amyloid Monoclonal Antibodies
- PMID: 39893023
- DOI: 10.1016/j.mcna.2024.10.003
Alzheimer's Disease Diagnosis and Management in the Age of Amyloid Monoclonal Antibodies
Abstract
Alzheimer's disease (AD) is the most common neurodegenerative disorder, and for providers the term AD is often avoided, favoring generic terms like memory loss or dementia. This is partly not only by limitations in using diagnostics and busy clinics but also by a sense that an AD diagnosis will not lead to a meaningful change in management. However, a turning point has occurred with advancements in diagnostics and disease-modifying therapies. Additionally, AD prevention therapies are not too far into the future. This review will cover AD clinical presentation and symptomatic management with focus on AD diagnostics and disease-modifying therapies.
Keywords: APOE; ARIA; Alzheimer’s disease; Amyloid brain PET; Donanemab; Lecanemab.
Copyright © 2024 Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosures The author has participated in industry-sponsored clinical trials for Alzheimer’s disease and frontotemporal dementia. Funding for trials is managed through the Emory Office of Sponsored Programs and there are no direct financial relationships between companies and the author.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
